Interleukin-6 induces neuroendocrine differentiation (NED) through suppression of RE-1 silencing transcription factor (REST)

Prostate

Volumn 74, Issue 11, 2014, Pages 1086-1094

  Zhu, Yezi ^a   Liu, Chengfei ^a   Cui, Yuanyuan ^a   Nadiminty, Nagalakshmi ^a   Lou, Wei ^a   Gao, Allen C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

interleukin 6; neuroendocrine; prostate cancer; REST

Indexed keywords

DEUBIQUITINASE; INTERLEUKIN 6; PROTEASOME; PROTEIN VP16; RE1 SILENCING TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR; UBIQUITIN; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; HERPES SIMPLEX; LNCAP CELL LINE; NERVE CELL DIFFERENTIATION; NEUROENDOCRINE PROSTATE CANCER; NEUROSECRETORY CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN DOMAIN;

INTERLEUKIN-6; NEUROENDOCRINE; PROSTATE CANCER; REST;

CELL DIFFERENTIATION; CELL LINE, TUMOR; CHROMOGRANIN A; DOWN-REGULATION; HUMANS; INTERLEUKIN-6; MALE; NEUROENDOCRINE TUMORS; PHENOTYPE; PHOSPHOPYRUVATE HYDRATASE; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; SYNAPTOPHYSIN; TUMOR MARKERS, BIOLOGICAL; UBIQUITIN;

EID: 84903126827     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22819     Document Type: Article

References (26)

1. Komiya A, Suzuki H, Imamoto T, Kamiya N, Nihei N, Naya Y, Ichikawa T, Fuse H,. Neuroendocrine differentiation in the progression of prostate cancer. Int J Urol 2009; 16 (1): 37-44.
2. Yang JC, Ok J-H, Busby JE, Borowsky AD, Kung HJ, Evans CP,. Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer. Cancer Res 2009; 69 (1): 151-160.
3. Yuan T-C, Veeramani S, Lin M-F,. Neuroendocrine-like prostate cancer cells: Neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer 2007; 14 (3): 531-547.
4. Dutt SS, Gao AC,. Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncol 2009; 5 (9): 1403-1413.
5. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST, Dhir R, Nelson JB, de la Taille A, Allory Y, Gerstein MB, Perner S, Pienta KJ, Chinnaiyan AM, Wang Y, Collins CC, Gleave ME, Demichelis F, Nanus DM, Rubin MA,. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011; 1 (6): 487-495.
6. Lee SO, Chun JY, Nadiminty N, Lou W, Gao AC,. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate 2007; 67 (7): 764-773.
7. Ge D, Gao AC, Zhang Q, Liu S, Xue Y, You Z,. LNCaP prostate cancer cells with autocrine interleukin-6 expression are resistant to IL-6-induced neuroendocrine differentiation due to increased expression of suppressors of cytokine signaling. Prostate 2012; 72 (12): 1306-1316.
8. Hobisch A, Rogatsch H, Hittmair A, Fuchs D, Bartsch G Jr, Klocker H, Bartsch G, Culig Z,. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol 2000; 191 (3): 239-244.
9. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC,. Elevated levels of circulating interleukin-6 and transforming growth factor-beta 1 in patients with metastatic prostatic carcinoma. J Urol 1999; 161 (1): 182-187.
10. Drachenberg DE, Elgamal A-AA, Rowbotham R, Peterson M, Murphy GP,. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 1999; 41 (2): 127-133.
11. Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC,. Interleukin-6 induces prostate cancer cell growth accompanied by activation of Stat3 signaling pathway. Prostate 2000; 42 (3): 239-242.
12. Zhu Y, Tummala R, Liu C, Nadiminty N, Lou W, Gao AC,. RhoGDIα suppresses growth and survival of prostate cancer cells. Prostate 2012; 72 (4): 392-398.
13. Majumader S,. REST in good times and bad: Roles in tumor suppressor and oncogenic activities. Cell Cycle 2006; 5 (17): 1929-1935.
14. Shimojo M, Shudo Y, Ikeda M, Kobashi T, Ito S,. The small cell lung cancer-specific isoform of RE1-silencing transcription factor (REST) is regulated by neural-specific Ser/Arg repeat-related protein of 100kDa (nSR100). Mol Cancer Res 2013; 11 (10): 1258-1268.
15. Reddy BY, Greco SJ, Patel PS, Trzaska KA, Rameshwar P,. RE-1-silencing transcription factor shows tumor-suppressor functions and negatively regulates the oncogenic TAC1 in breast cancer cells. Proc Natl Acad Sci USA 2009; 106 (11): 4408-4413.
16. Lapuk AV, Wu C, Wyatt AW, McPherson A, McConeghy BJ, Brahmbhatt S, Mo F, Zoubeidi A, Anderson S, Bell RH, Haegert A, Shukin R, Wang Y, Fazli L, Hurtado-Coll A, Jones EC, Hach F, Hormozdiari F, Hajirasouliha I, Boutros PC, Bristow RG, Zhao Y, Marra MA, Fanjul A, Maher CA, Chinnaiyan AM, Rubin MA, Beltran H, Sahinalp SC, Gleave ME, Volik SV, Collins CC,. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol 2012; 227 (3): 286-297.
17. Negrini S, Prada I, D'Alessandro R, Meldolesi J,. REST: An oncogene or a tumor suppressor ? Trends Cell Biol 2013; 23 (6): 289-295.
18. Huang J, Wu C, di Sant'Agnese PA, Yao JL, Cheng L, Na Y,. Function and molecular mechanisms of neuroendocrine cells in prostate cancer. Anal Quant Cytol Histol 2007; 29 (3): 128-138.
19. Immaneni A, Lawinger P, Zhao Z, Lu W, Rastelli L, Morris JH, Majumder S,. REST-VP16 activates multiple neuronal differentiation genes in human NT2 cells. Nucleic Acids Res 2000; 28 (17): 3403-3410.
20. Huang Z, Wu Q, Guryanova OA, Cheng L, Shou W, Rich JN, Bao S,. Deubiquitylase HAUSP stabilizes REST and promotes maintenance of neural progenitor cells. Nat Cell Biol 2011; 13 (2): 142-152.
21. Westbrook TF, Hu G, Ang XL, Mulligan P, Pavlova NN, Liang A, Leng Y, Maehr R, Shi Y, Harper JW, Elledge SJ,. SCFbeta-TRCP controls oncogenic transformation and neural differentiation through REST degradation. Nature 2008; 452 (7183): 370-374.
22. Deeble PD, Marphy DJ, Parsons SJ, Cox ME,. Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol 2001; 21 (24): 8471-8482.
23. Spiotto MT, Chung TDK,. STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate 2000; 42 (3): 186-195.
24. Westbrook TF, Martin ES, Schlabach MR, Leng Y, Liang AC, Feng B, Zhao JJ, Roberts TM, Mandel G, Hannon GJ, Depinho RA, Chin L, Elledge SJ,. A genetic screen for candidate tumor suppressors identifies REST. Cell 2005; 121 (6): 837-848.
25. Svensson C, Ceder J, Iglesias-Gato D, Chuan YC, Pang ST, Bjartell A, Martinez RM, Bott L, Helczynski L, Ulmert D, Wang Y, Niu Y, Collins C, Flores-Morales A,. REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer. Nucleic Acids Res 2014; 42 (2): 999-1015.
26. Liang H, Studach L, Hullinger RL, Xie J, Andrisani OM,. Down-regulation of RE-1 silencing transcription factor (REST) in advanced prostate cancer by hypoxia-induced miR-106b∼25. Exp Cell Res 2014; 320 (2): 188-199.